CD274 and neoplasm: Pembrolizumab, a humanized monoclonal antibody against PD-1, became the first ICI approved as a first-line monotherapy for patients with high PD-L1 expression (tumor proportion score [TPS] ≥ 50%) and no actionable driver mutations, based on the results of the KEYNOTE-024 trial [5].